Article
BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 7 Aug 2023
Lanjouw Lieke, Mourits Marian J E, Bart Joost, Ter Elst Arja, Berger Lieke P V, van der Hout Annemieke H, Alam Naufil, de Bock Geertruida H
Abstract excerpt
BACKGROUND: Since 2015, Dutch guidelines have recommended BRCA1/2 pathogenic variant testing for all patients with epithelial ovarian cancer. Recently, recommendations shifted from germline testing to the tumor-first approach, in which tumor tissue is tested first, and subsequent germline testing is performed only in those with BRCA1/2 tumor pathogenic variants or a positive family history. Data on testing rates...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.